Inovio Pharmaceuticals, Inc. $INO

What the company doesAI summary of filing

Inovio Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines—circular DNA plasmids designed to instruct cells to produce disease-fighting proteins—delivered using proprietary electroporation devices called CELLECTRA. The company's lead candidate, INO-3107, treats recurrent respiratory papillomatosis (RRP), a rare HPV-related disease; its BLA was accepted by the FDA in December 2025 with a target decision date of October 30, 2026. Inovio's pipeline also includes candidates for HPV-related cancers, glioblastoma, infectious diseases, and protein replacement therapies, with funding from government agencies and collaborators including AstraZeneca, Coherus Biosciences, and NIH. The company is pre-revenue, generating only milestone payments and research collaboration fees, with substantial doubt about its ability to continue operations without additional capital. [10-K 2026-03-12]

Segments: INO-3107 (RRP/HPV-related diseases), INO-3112 (oropharyngeal squamous cell carcinoma), INO-5401/INO-5412 (glioblastoma and BRCA-related cancers), Infectious disease candidates (COVID-19, Ebola, HIV)